Partners Group Forecast, price target & analysts
Partners Group Target price 2025 - Analyst rating & recommendation
Partners Group Classifications & Recommendation:
Partners Group Price Target
| Target Price | CHF1,203.60 |
| Price | CHF1,009.00 |
| Potential | 19.29% |
| Number of Estimates | 16 |
| 16 Analysts have issued a price target Partners Group 2026 . The average Partners Group target price is CHF1,203.60. This is 19.29% higher than the current stock price. The highest price target is CHF1,470.00 45.69% , the lowest is CHF1,131.20 12.11% . | |
| A rating was issued by 21 analysts: 11 Analysts recommend Partners Group to buy, 9 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Partners Group stock has an average upside potential 2026 of 19.29% . Most analysts recommend the Partners Group stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 2.02 | 2.47 |
| 8.71% | 22.43% | |
| EBITDA Margin | 67.25% | 63.17% |
| 1.21% | 6.07% | |
| Net Margin | 55.87% | 50.88% |
| 3.38% | 8.94% |
17 Analysts have issued a sales forecast Partners Group 2025 . The average Partners Group sales estimate is CHF2.5b . This is 10.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF2.7b 22.77% , the lowest is CHF2.0b 9.60% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF2.0b | 8.71% |
|---|---|---|
| 2025 | CHF2.5b | 22.43% |
| 2026 | CHF2.8b | 13.31% |
| 2027 | CHF3.3b | 16.46% |
| 2028 | CHF3.3b | 0.09% |
| 2029 | CHF3.5b | 8.21% |
16 Analysts have issued an Partners Group EBITDA forecast 2025. The average Partners Group EBITDA estimate is CHF1.6b . This is 6.69% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF1.7b 17.83% , the lowest is CHF1.3b 13.47% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF1.4b | 10.03% |
|---|---|---|
| 2025 | CHF1.6b | 15.00% |
| 2026 | CHF1.8b | 12.62% |
| 2027 | CHF2.1b | 17.01% |
| 2028 | CHF2.1b | 0.29% |
| 2029 | CHF2.2b | 6.98% |
EBITDA Margin
| 2024 | 67.25% | 1.21% |
|---|---|---|
| 2025 | 63.17% | 6.07% |
| 2026 | 62.79% | 0.60% |
| 2027 | 63.08% | 0.46% |
| 2028 | 63.20% | 0.19% |
| 2029 | 62.49% | 1.12% |
18 Partners Group Analysts have issued a net profit forecast 2025. The average Partners Group net profit estimate is CHF1.3b . This is 4.96% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF1.4b 18.43% , the lowest is CHF1.0b 12.63% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF1.1b | 12.39% |
|---|---|---|
| 2025 | CHF1.3b | 11.49% |
| 2026 | CHF1.4b | 12.27% |
| 2027 | CHF1.6b | 16.63% |
| 2028 | CHF1.7b | 0.68% |
| 2029 | CHF1.8b | 8.62% |
Net Margin
| 2024 | 55.87% | 3.38% |
|---|---|---|
| 2025 | 50.88% | 8.94% |
| 2026 | 50.41% | 0.92% |
| 2027 | 50.49% | 0.16% |
| 2028 | 50.78% | 0.57% |
| 2029 | 50.97% | 0.37% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 43.08 | 48.47 |
| 11.75% | 12.51% | |
| P/E | 20.71 | |
| EV/Sales | 11.70 |
18 Analysts have issued a Partners Group forecast for earnings per share. The average Partners Group EPS is CHF48.47 . This is 5.21% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF54.69 18.71% , the lowest is CHF40.35 12.42% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF43.08 | 11.75% |
|---|---|---|
| 2025 | CHF48.47 | 12.51% |
| 2026 | CHF54.42 | 12.28% |
| 2027 | CHF63.47 | 16.63% |
| 2028 | CHF63.90 | 0.68% |
| 2029 | CHF69.40 | 8.61% |
P/E ratio
| Current | 21.79 | 37.09% |
|---|---|---|
| 2025 | 20.71 | 4.97% |
| 2026 | 18.45 | 10.91% |
| 2027 | 15.82 | 14.25% |
| 2028 | 15.71 | 0.70% |
| 2029 | 14.47 | 7.89% |
Based on analysts' sales estimates for 2025, the Partners Group stock is valued at an EV/Sales of 11.70 and an P/S ratio of 10.58 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 12.97 | 36.61% |
|---|---|---|
| 2025 | 11.70 | 9.77% |
| 2026 | 10.33 | 11.75% |
| 2027 | 8.87 | 14.14% |
| 2028 | 8.86 | 0.09% |
| 2029 | 8.19 | 7.59% |
P/S ratio
| Current | 11.73 | 39.88% |
|---|---|---|
| 2025 | 10.58 | 9.75% |
| 2026 | 9.34 | 11.75% |
| 2027 | 8.02 | 14.14% |
| 2028 | 8.01 | 0.09% |
| 2029 | 7.40 | 7.59% |
Current Partners Group Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ROTHSCHILD & CO REDBURN |
Neutral
➜
Neutral
|
Unchanged | Sep 08 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Buy
➜
Buy
|
Unchanged | Sep 02 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Sep 02 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Buy
➜
Buy
|
Unchanged | Jul 16 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Jul 15 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Buy
➜
Buy
|
Unchanged | Jul 15 2025 |
| ROTHSCHILD & CO REDBURN |
Neutral
➜
Neutral
|
Unchanged | Jul 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
ROTHSCHILD & CO REDBURN:
Neutral
➜
Neutral
|
Sep 08 2025 |
|
Unchanged
BAADER HELVEA EQUITY RESEARCH:
Buy
➜
Buy
|
Sep 02 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Sep 02 2025 |
|
Unchanged
BAADER HELVEA EQUITY RESEARCH:
Buy
➜
Buy
|
Jul 16 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Jul 15 2025 |
|
Unchanged
BAADER HELVEA EQUITY RESEARCH:
Buy
➜
Buy
|
Jul 15 2025 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Neutral
➜
Neutral
|
Jul 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
